Primary Membranous Nephropathy Clinical Trials

17 recruitingLast updated: May 21, 2026

There are 17 actively recruiting primary membranous nephropathy clinical trials across 26 countries. Studies span Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Houston, Texas, United States, Los Angeles, California, United States, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


Primary Membranous Nephropathy Trials at a Glance

17 actively recruiting trials for primary membranous nephropathy are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Guangzhou. Lead sponsors running primary membranous nephropathy studies include First Affiliated Hospital, Sun Yat-Sen University, Shanghai Jiaolian Drug Research and Development Co., Ltd, and Biogen.

Browse primary membranous nephropathy trials by phase

About Primary Membranous Nephropathy Clinical Trials

Looking for clinical trials for Primary Membranous Nephropathy? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Membranous Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Membranous Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.96 enrolled18 locationsNCT06557265
Recruiting
Phase 2Phase 3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled93 locationsNCT07204275
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Biogen180 enrolled93 locationsNCT06962800
Recruiting
Phase 2

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Primary Membranous Nephropathy
AstraZeneca43 enrolled21 locationsNCT07571746
Recruiting
Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd52 enrolled6 locationsNCT05668403
Recruiting
Phase 2Phase 3

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd216 enrolled21 locationsNCT06470191
Recruiting
Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Climb Bio, Inc.45 enrolled45 locationsNCT07096843
Recruiting
Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.30 enrolled40 locationsNCT07157787
Recruiting
Phase 4

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University116 enrolled1 locationNCT06573411
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
Phase 2

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd75 enrolled1 locationNCT07289763
Recruiting
Phase 3

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Primary Membranous Nephropathy
Huashan Hospital144 enrolled1 locationNCT06781944
Recruiting
Phase 1

Study of YK012 in Primary Membranous Nephropathy

Primary Membranous Nephropathy
Excyte Biopharma Ltd72 enrolled1 locationNCT06982729
Recruiting

A Real World Study About PMN

Primary Membranous Nephropathy
Wei Chen200 enrolled1 locationNCT06893328
Recruiting
Phase 1

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Primary Membranous Nephropathy
Everest Medicines (China) Co.,Ltd.30 enrolled19 locationsNCT05800873
Recruiting
Phase 3

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Cerium Pharmaceuticals, Inc.148 enrolled31 locationsNCT05696613
Recruiting
Phase 4

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University78 enrolled1 locationNCT05514015